Research Continues: Join the Discovery on Target Virtual Community

As the coronavirus situation further develops, the health and well-being of our community remains our top priority. We would never have dreamt our world would be facing such uncertain times. Our team has been working for months behind the scenes planning the 2020 event, monitoring and adapting to these new circumstances. We’re excited we can still support your scientific collaborations – now virtually – this fall.

Discovery on Target (DOT) is the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. DOT highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

We aim to meet your research needs. Delegates can virtually visit numerous concurrent sessions and – with on-demand access to presentations – benefit even from those you can’t attend live. You can customize your experience further through focused short courses, interactive breakout discussions, and virtual networking options that help you engage with experts and solutions providers from the comfort of home.

Discover the Benefits:

  • Drug discovery technology and business attendees ready for networking and mutual learning across time zones from the convenience of home
  • Poster presentations sharing a stimulating spectrum of research
  • Exhibiting and sponsoring companies revealing solutions to persistent challenges
  • Emerging “hot” targets and technologies for the discovery of novel therapeutics
  • Expanded coverage of biologics and additional topics on preclinical and translational research
  • Customizable experience allowing “track-hopping” between concurrent programs
  • NEW: On-demand virtual access that lets you benefit even from presentations you can’t attend live

September 16 - 17

Target Identification and Validation – Part 1Target Identification and Validation – Part 1

NEW
RNA as a Drug TargetRNA as a Drug Target
PROTACs and Targeted Protein Degradation – Part 1PROTACs and Targeted Protein Degradation – Part 1
Lead and Candidate Selection for Therapeutic ProteinsLead and Candidate Selection for Therapeutic Proteins

NEW
Antibodies Against Membrane Protein Targets – Part 1Antibodies Against Membrane Protein Targets – Part 1
Small G ProteinsSmall G Proteins

NEW
Immunology and Oncology: Emerging Drug Targets and TherapeuticsImmunology and Oncology
Targeting NASHTargeting NASH
Disease Modeling

 NEW
CNS, Gene and Cell Therapy

 NEW

September 17 - 18

Target Identification and Validation – Part 2Target Identification and Validation – Part 2
Lead Generation StrategiesLead Generation Strategies
PROTACs and Targeted Protein Degradation – Part 2PROTACs and Targeted Protein Degradation – Part 2
Modality Selection for Next-Gen Biotherapeutics

NEW
Antibodies Against Membrane Protein Targets – Part 2Antibodies Against Membrane Protein Targets – Part 2
Kinase Inhibitor DiscoveryKinase Inhibitor Discovery
GPCR-Based Drug Discovery GPCR-Based Drug Discovery
Targeting Fibrosis
Preclinical Strategies, Models and Tools in OncologyPreclinical Strategies, Models and Tools in Oncology

 NEW
Clinical and Translational BiomarkersClinical and Translational Biomarkers

 NEW